Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M C Mazeron

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
Nouvelle Revue Francaise D'Hematologie|January 1, 1990
Treatment of severe cytomegalovirus infection with ganciclovir and high-dose intravenous immunoglobulin in patients with allogeneic bone marrow transplants. A pilot studyP Lehn, A Quessar, A Devergie, et al.
Pathologie-Biologie|May 1, 1996
[Resistance of cytomegalovirus to ganciclovir: rapid detection of the mutations 460 of the UL97 phosphotransferase]S Alain, M C Mazeron, C Vadam, et al.
Revue Francaise De Transfusion Et Immuno-Hematologie|November 1, 1987
[Post-transfusion cytomegalovirus infections. The position in 1987]G Andreu, P Bierling, Y Brossard, et al.
Antiviral Research|February 14, 2016
Contrasting effect of new HCMV pUL54 mutations on antiviral drug susceptibility: Benefits and limits of 3D analysisD Andouard, M-C Mazeron, G Ligat, et al.
AIDS (London, England)|June 15, 2000
Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapyD Salmon-Céron, M C Mazeron, S Chaput, et al.
Journal of Medical Virology|June 29, 2004
Detection of ganciclovir resistance after valacyclovir-prophylaxis in renal transplant recipients with active cytomegalovirus infectionS Alain, S Hantz, C Scieux, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|December 3, 2015
Response to antiviral therapy in haematopoietic stem cell transplant recipients with cytomegalovirus (CMV) reactivation according to the donor CMV serological statusS Servais, N Dumontier, L Biard, et al.
Ebiomedicine|December 24, 2017
What Is the most Important for Elite Control: Genetic Background of Patient, Genetic Background of Partner, both or neither? Description of Complete Natural History within a Couple of MSMM Bendenoun, A Samri, V Avettand-Fènoël, et al.
Transplantation Proceedings|June 4, 2013
Maribavir use in practice for cytomegalovirus infection in French transplantation centersS Alain, M Revest, D Veyer, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Nouvelle Revue Francaise D'Hematologie|January 1, 1990
Treatment of severe cytomegalovirus infection with ganciclovir and high-dose intravenous immunoglobulin in patients with allogeneic bone marrow transplants. A pilot studyP Lehn, A Quessar, A Devergie, et al.
Pathologie-Biologie|May 1, 1996
[Resistance of cytomegalovirus to ganciclovir: rapid detection of the mutations 460 of the UL97 phosphotransferase]S Alain, M C Mazeron, C Vadam, et al.
Revue Francaise De Transfusion Et Immuno-Hematologie|November 1, 1987
[Post-transfusion cytomegalovirus infections. The position in 1987]G Andreu, P Bierling, Y Brossard, et al.
Antiviral Research|February 14, 2016
Contrasting effect of new HCMV pUL54 mutations on antiviral drug susceptibility: Benefits and limits of 3D analysisD Andouard, M-C Mazeron, G Ligat, et al.
AIDS (London, England)|June 15, 2000
Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapyD Salmon-Céron, M C Mazeron, S Chaput, et al.
Journal of Medical Virology|June 29, 2004
Detection of ganciclovir resistance after valacyclovir-prophylaxis in renal transplant recipients with active cytomegalovirus infectionS Alain, S Hantz, C Scieux, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|December 3, 2015
Response to antiviral therapy in haematopoietic stem cell transplant recipients with cytomegalovirus (CMV) reactivation according to the donor CMV serological statusS Servais, N Dumontier, L Biard, et al.
Ebiomedicine|December 24, 2017
What Is the most Important for Elite Control: Genetic Background of Patient, Genetic Background of Partner, both or neither? Description of Complete Natural History within a Couple of MSMM Bendenoun, A Samri, V Avettand-Fènoël, et al.
Transplantation Proceedings|June 4, 2013
Maribavir use in practice for cytomegalovirus infection in French transplantation centersS Alain, M Revest, D Veyer, et al.
Pageof 6